Low dosis of alteplase, for ischemic stroke after Enchanted and its determinants, a single center experience.
Alejandro Michel BrunserEnrico MazzonGabriel CavadaEloy MansillaAlexis RojoJuan AlmeidaVerónica Viviana OlavarríaPaula Muñoz VenturelliPablo Manuel LavadosPublished in: Arquivos de neuro-psiquiatria (2020)
Following the ENCHANTED trial, LrtPA was restricted to 30% of our patients. The criteria that clinicians apply are based mostly on clinical variables that may increase the risk of brain or systemic hemorrhage or exclude the patient from treatment with lytic drugs.